- Home
- SNDX vs OMDA Comparison
SNDX vs OMDA Comparison
Compare SNDX & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- OMDA
- Stock Information
- Founded
- SNDX 2005
- OMDA 2011
- Country
- SNDX United States
- OMDA United States
- Employees
- SNDX N/A
- OMDA N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- OMDA Medical/Nursing Services
- Sector
- SNDX Health Care
- OMDA Health Care
- Exchange
- SNDX Nasdaq
- OMDA Nasdaq
- Market Cap
- SNDX 1.1B
- OMDA 1.3B
- IPO Year
- SNDX 2016
- OMDA 2025
- Fundamental
- Price
- SNDX $9.92
- OMDA $17.52
- Analyst Decision
- SNDX Strong Buy
- OMDA Strong Buy
- Analyst Count
- SNDX 11
- OMDA 6
- Target Price
- SNDX $34.00
- OMDA $24.17
- AVG Volume (30 Days)
- SNDX 1.7M
- OMDA 426.7K
- Earning Date
- SNDX 08-04-2025
- OMDA 08-07-2025
- Dividend Yield
- SNDX N/A
- OMDA N/A
- EPS Growth
- SNDX N/A
- OMDA N/A
- EPS
- SNDX N/A
- OMDA N/A
- Revenue
- SNDX $43,722,000.00
- OMDA $189,668,000.00
- Revenue This Year
- SNDX $431.08
- OMDA $33.26
- Revenue Next Year
- SNDX $105.38
- OMDA $20.16
- P/E Ratio
- SNDX N/A
- OMDA N/A
- Revenue Growth
- SNDX N/A
- OMDA 38.29
- 52 Week Low
- SNDX $8.58
- OMDA $14.14
- 52 Week High
- SNDX $23.37
- OMDA $28.40
- Technical
- Relative Strength Index (RSI)
- SNDX 51.66
- OMDA N/A
- Support Level
- SNDX $9.42
- OMDA N/A
- Resistance Level
- SNDX $10.75
- OMDA N/A
- Average True Range (ATR)
- SNDX 0.58
- OMDA 0.00
- MACD
- SNDX 0.08
- OMDA 0.00
- Stochastic Oscillator
- SNDX 51.74
- OMDA 0.00
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.